Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf593 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Marian Loveday und 8 weiteren Autor:innen. Beteiligte Einrichtung: HIV and Other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa. Hauptthemen laut MEDLINE: Tuberculosis, Multidrug-Resistant, Antitubercular Agents, Pregnancy Complications, Infectious, Pregnancy Outcome. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
There is limited information on the safety and efficacy of new and repurposed second-line anti-tuberculosis (TB) drugs in pregnant women.
Methods
Pregnant women initiating treatment for multidrug-resistant/rifampicin-resistant (MDR/RR) TB from 1 January 2018 to 31 March 2024 were included in this prospective, observational study. Maternal TB treatment and pregnancy outcomes were documented through ongoing record reviews and clinical assessments conducted to describe infant outcomes. Using Poisson regression with robust standard errors, we evaluated factors associated with favorable maternal treatment and pregnancy outcomes.
Results
Of 70 pregnant women treated for MDR/RR TB, 53 (76%) were living with human immunodeficiency virus (HIV). Favorable TB treatment outcomes were reported in 44 (62.9%) women. Sixty-seven (95.7%) of the 70 infants were born alive;median gestational age 38 weeks (interquartile range [IQR], 37.0–39.0) and median birth weight 2970 g (IQR, 2560–3280). All infants were exposed to bedaquiline. Twenty-three (34.3%) women had unfavorable pregnancy outcomes, with 20 (29.8%) infants born prematurely and/or with low birth weight. Women with positive sputum smears at treatment initiation were less likely to have a favorable treatment outcome (adjusted risk ratio, 0.33; 95% confidence interval, .17–.66; P = .002). Of the 43 infants evaluated at 12 months, 27 (62.8%) had favorable outcomes, with 10 (23.3%) infants developing TB in their first year of life.
Conclusions
The high TB–HIV coinfection rate is likely to have contributed to unfavorable pregnancy outcomes. Supportive maternal adherence counseling and infant TB preventive treatment are needed to prevent TB transmission to infants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIV and Other Infectious Diseases Research Unit, South African Medical Research Council, Durban, South Africa.
- SAMRC-CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Centre for the AIDS programme of Research in South Africa, University of KwaZulu-Natal, Durban, South Africa.
- Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
- Biostatistics Research Unit, South African Medical Research Council, Durban, South Africa.
- MDR/RR-TB Unit, King Dinuzulu Hospital Complex, Sydenham, Durban, South Africa.
- Department of Infectious Disease, Imperial College London, London, United Kingdom.
ORCID-Profile: Marian Loveday, Jennifer Hughes, James A Seddon
Zitieren
APA
Loveday, M., Hughes, J., Mchunu, N., Yende-Zuma, N., Holloway, K., Hlangu, S., Chotoo, S., Singh, N., & Seddon, J. A. (2025). Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf593
Vancouver
Loveday M, Hughes J, Mchunu N, Yende-Zuma N, Holloway K, Hlangu S, et al. Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf593
BibTeX
@article{Loveday2025,
author = {Loveday, Marian and Hughes, Jennifer and Mchunu, Nobuhle and Yende-Zuma, Nonhlanhla and Holloway, Kerry and Hlangu, Sindisiwe and Chotoo, Sunitha and Singh, Nalini and Seddon, James A},
title = {Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf593}
}
EUVIMED